Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Diuretic Resistance in Heart Failure, Aim 2
NCT05753059Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Aug 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bendroflumethiazide and amiloride in heart failure (HF) (4 arms), sponsored by Yale University. Primary endpoints: Change in peak fractional excretion of sodium at 21 days, Change in distal sodium reabsorption at 21 days and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
bendroflumethiazideamiloride
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05753059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753059.